These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28276283)

  • 1. Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1.
    Kang D; Huo Z; Wu G; Xu J; Zhan P; Liu X
    Expert Opin Ther Pat; 2017 Apr; 27(4):383-391. PubMed ID: 28276283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419.
    Meng Q; Liu N; Huang B; Zhan P; Liu X
    Expert Opin Ther Pat; 2015; 25(12):1477-86. PubMed ID: 26415039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.
    Huang B; Kang D; Yang J; Zhan P; Liu X
    Expert Opin Ther Pat; 2016; 26(2):281-9. PubMed ID: 26559996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
    Rai D; Chen W; Tian Y; Chen X; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem; 2013 Dec; 21(23):7398-405. PubMed ID: 24134904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
    Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Sang Y; Han S; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Eur J Med Chem; 2019 Nov; 182():111603. PubMed ID: 31421633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.
    Šimon P; Baszczyňski O; Šaman D; Stepan G; Hu E; Lansdon EB; Jansa P; Janeba Z
    Eur J Med Chem; 2016 Oct; 122():185-195. PubMed ID: 27371922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Gu SX; Lu HH; Liu GY; Ju XL; Zhu YY
    Eur J Med Chem; 2018 Oct; 158():371-392. PubMed ID: 30223123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2020 Mar; 96():103595. PubMed ID: 32006797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2-
    Zhuo Z; Wang Z; Jing L; Zhang T; Ge A; Zhou Z; Liu Y; Li X; De Clercq E; Pannecouque C; Zhan P; Liu X; Kang D
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Tian XT; Xie L
    Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2,4,6-trisubstituted pyrimidine derivatives as novel potent HIV-1 NNRTIs by exploiting the tolerant region II of the NNIBP.
    Zhou Z; Sun Y; Qin Y; Wang N; Zhao F; Wang Z; Clercq E; Pannecouque C; Zhan P; Kang D; Liu X
    Eur J Med Chem; 2024 Nov; 277():116708. PubMed ID: 39094273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach.
    Li X; Chen W; Tian Y; Liu H; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Eur J Med Chem; 2014 Jun; 80():112-21. PubMed ID: 24769349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Wu HQ; Yao J; He QQ; Chen WX; Chen FE; Pannecouque C; De Clercq E; Daelemans D
    Bioorg Med Chem; 2015 Feb; 23(3):624-31. PubMed ID: 25537532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
    Wang L; Tian Y; Chen W; Liu H; Zhan P; Li D; Liu H; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2014 Oct; 85():293-303. PubMed ID: 25089812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
    Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
    Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
    Tian Y; Du D; Rai D; Wang L; Liu H; Zhan P; De Clercq E; Pannecouque C; Liu X
    Bioorg Med Chem; 2014 Apr; 22(7):2052-9. PubMed ID: 24631361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.